{"id":51051,"date":"2022-11-18T19:02:03","date_gmt":"2022-11-18T18:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/"},"modified":"2022-11-18T19:02:03","modified_gmt":"2022-11-18T18:02:03","slug":"the-native-antigen-company-introduces-new-range-of-influenza-antigens","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/","title":{"rendered":"The Native Antigen Company Introduces New Range of Influenza Antigens"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes<\/i>\n<\/li>\n<li>\n<i>New range developed to cover 2023 southern hemisphere flu season<\/i>\n<\/li>\n<\/ul>\n<p>OXFORD, England&#8211;(BUSINESS WIRE)&#8211;The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world\u2019s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere\u2019s 2023 flu season. The latest influenza antigens will help support development of vaccines and diagnostics as part of the ongoing vaccine reformulation programme, helping to ensure public safety throughout the annual flu season.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/5\/New_Logo_V1_%28002%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg\"><\/a><\/p>\n<p>\nIn February and September of each year, the World Health Organization (WHO) announces flu vaccine formulations for the northern and southern hemispheres. To support vaccine research and development, The Native Antigen Company has developed Haemagglutinin and Neuraminidase antigens for the WHO-recommended, egg-based and recombinant vaccine strains. Available in bulk quantities, the latest range of antigens can be used in a range of applications, including immunoassay development and as immunogens, and includes reagents for both influenza A and B.\n<\/p>\n<p>\nThe Native Antigen Company\u2019s influenza antigens were developed using the Company\u2019s proprietary mammalian expression system, VirtueE. The antigen exhibits full glycosylation and folding to ensure that antibodies raised against it are highly specific. The Haemagglutinin antigens feature C-terminal T4 foldon domains, stabilising them in their trimeric conformation to present more native-like conformational epitopes.\n<\/p>\n<p>\n<b>Ish Jalal, Commercial Director, The Native Antigen Company, said:<\/b> <i>\u201cEach year, we are proud to be able to support vaccine and diagnostic manufacturers by updating our range of influenza reagents in line with WHO\u2019s guidance. Our customers now have access to the very latest, high-quality antigens for vaccine reformulation, to ensure the public continues to stay safe during the 2023 flu season.\u201d<\/i>\n<\/p>\n<p>\nFor further information about The Native Antigen Company\u2019s influenza range, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fthenativeantigencompany.com%2Finfluenza-vaccine-antigens%2F&amp;esheet=52973041&amp;newsitemid=20221118005468&amp;lan=en-US&amp;anchor=https%3A%2F%2Fthenativeantigencompany.com%2Finfluenza-vaccine-antigens%2F&amp;index=1&amp;md5=51ed487bab95bba9ee5cfaeda7574a8d\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/thenativeantigencompany.com\/influenza-vaccine-antigens\/<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nZyme Communications<br \/>\n<br \/>Lorna Cuddon<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x6c;o&#x72;n&#x61;&#46;&#x63;u&#100;&#x64;&#111;&#x6e;&#64;&#x7a;&#121;&#x6d;&#101;&#x63;o&#x6d;m&#x75;n&#x69;c&#97;&#x74;&#105;&#x6f;&#110;&#x73;&#46;&#x63;&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#108;&#x6f;r&#x6e;&#x61;&#46;&#x63;u&#x64;&#x64;&#111;&#x6e;&#64;&#x7a;&#x79;&#109;&#x65;c&#x6f;&#x6d;&#109;&#x75;n&#x69;&#x63;&#97;&#x74;i&#x6f;&#x6e;&#115;&#x2e;c&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes New range developed to cover 2023 southern hemisphere flu season OXFORD, England&#8211;(BUSINESS WIRE)&#8211;The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world\u2019s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51051","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The Native Antigen Company Introduces New Range of Influenza Antigens - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Native Antigen Company Introduces New Range of Influenza Antigens - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes New range developed to cover 2023 southern hemisphere flu season OXFORD, England&#8211;(BUSINESS WIRE)&#8211;The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world\u2019s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-18T18:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"The Native Antigen Company Introduces New Range of Influenza Antigens\",\"datePublished\":\"2022-11-18T18:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/\"},\"wordCount\":336,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221118005468\\\/en\\\/1642958\\\/21\\\/New_Logo_V1_%28002%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/\",\"name\":\"The Native Antigen Company Introduces New Range of Influenza Antigens - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221118005468\\\/en\\\/1642958\\\/21\\\/New_Logo_V1_%28002%29.jpg\",\"datePublished\":\"2022-11-18T18:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221118005468\\\/en\\\/1642958\\\/21\\\/New_Logo_V1_%28002%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221118005468\\\/en\\\/1642958\\\/21\\\/New_Logo_V1_%28002%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Native Antigen Company Introduces New Range of Influenza Antigens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Native Antigen Company Introduces New Range of Influenza Antigens - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/","og_locale":"en_US","og_type":"article","og_title":"The Native Antigen Company Introduces New Range of Influenza Antigens - Pharma Trend","og_description":"Season-specific Haemagglutinin and Neuraminidase antigens will support vaccine and diagnostic reformulation programmes New range developed to cover 2023 southern hemisphere flu season OXFORD, England&#8211;(BUSINESS WIRE)&#8211;The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world\u2019s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-18T18:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"The Native Antigen Company Introduces New Range of Influenza Antigens","datePublished":"2022-11-18T18:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/"},"wordCount":336,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/","url":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/","name":"The Native Antigen Company Introduces New Range of Influenza Antigens - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg","datePublished":"2022-11-18T18:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221118005468\/en\/1642958\/21\/New_Logo_V1_%28002%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/the-native-antigen-company-introduces-new-range-of-influenza-antigens\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"The Native Antigen Company Introduces New Range of Influenza Antigens"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51051"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51051\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}